Victory Capital Management
IOVA icon

Victory Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Victory Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$142K Buy
40,463
+1,470
+4% +$4.7K ﹤0.01% 2241
2025
Q4 		$106K Buy
38,993
+5,287
+16% +$12.2K ﹤0.01% 2265
2025
Q3 		$73.1K Buy
33,706
+1,322
+4% +$3.12K ﹤0.01% 2319
2025
Q2 		$55.7K Buy
32,384
+333
+1% +$829 ﹤0.01% 2369
2025
Q1 		$107K Sell
32,051
-109,429
-77% -$564K ﹤0.01% 2304
2024
Q4 		$1.05M Sell
141,480
-2,800
-2% -$26K ﹤0.01% 1791
2024
Q3 		$1.35M Buy
144,280
+115,387
+399% +$1.09M ﹤0.01% 1645
2024
Q2 		$232K Sell
28,893
-64
-0.2% -$686 ﹤0.01% 2165
2024
Q1 		$429K Buy
28,957
+2,036
+8% +$23.7K ﹤0.01% 2031
2023
Q4 		$219K Buy
26,921
+4,323
+19% +$22.6K ﹤0.01% 2212
2023
Q3 		$103K Buy
22,598
+3,937
+21% +$25.7K ﹤0.01% 2297
2023
Q2 		$131K Sell
18,661
-434
-2% -$3.11K ﹤0.01% 2271
2023
Q1 		$117K Sell
19,095
-23,770
-55% -$164K ﹤0.01% 2337
2022
Q4 		$274K Sell
42,865
-99,897
-70% -$780K ﹤0.01% 2191
2022
Q3 		$1.37M Sell
142,762
-42,125
-23% -$486K ﹤0.01% 1599
2022
Q2 		$2.04M Sell
184,887
-38,450
-17% -$504K ﹤0.01% 1448
2022
Q1 		$3.67M Sell
223,337
-69,440
-24% -$1.07M ﹤0.01% 1348
2021
Q4 		$5.59M Sell
292,777
-16,875
-5% -$372K 0.01% 1302
2021
Q3 		$7.64M Sell
309,652
-77,430
-20% -$1.82M 0.01% 1180
2021
Q2 		$10.1M Sell
387,082
-1,513,108
-80% -$39.3M 0.01% 1127
2021
Q1 		$60.2M Sell
1,900,190
-124,764
-6% -$5.17M 0.06% 461
2020
Q4 		$94M Sell
2,024,954
-54,284
-3% -$2.16M 0.1% 277
2020
Q3 		$68.4M Sell
2,079,238
-181,000
-8% -$5.55M 0.09% 323
2020
Q2 		$62M Sell
2,260,238
-1,733,502
-43% -$57M 0.08% 348
2020
Q1 		$120M Buy
3,993,740
+1,545,553
+63% +$41M 0.1% 285
2019
Q4 		$67.8M Buy
2,448,187
+129,019
+6% +$2.93M 0.08% 360
2019
Q3 		$42.2M Buy
2,319,168
+311,425
+16% +$6.89M 0.05% 518
2019
Q2 		$49.2M Sell
2,007,743
-466,394
-19% -$7.02M 0.1% 314
2019
Q1 		$23.5M Sell
2,474,137
-547,790
-18% -$5.32M 0.05% 533
2018
Q4 		$26.7M Buy
3,021,927
+591,270
+24% +$5.7M 0.07% 462
2018
Q3 		$27.3M Buy
2,430,657
+86,378
+4% +$1.23M 0.06% 526
2018
Q2 		$30M Buy
2,344,279
+58,780
+3% +$859K 0.06% 490
2018
Q1 		$38.6M Buy
2,285,499
+184,336
+9% +$2.79M 0.08% 381
2017
Q4 		$16.8M Sell
2,101,163
-537,160
-20% -$4.31M 0.04% 616
2017
Q3 		$20.4M Buy
2,638,323
+51,450
+2% +$326K 0.05% 580
2017
Q2 		$19M Buy
2,586,873
+48,390
+2% +$308K 0.04% 589
2017
Q1 		$18.9M Buy
2,538,483
+197,638
+8% +$1.45M 0.05% 590
2016
Q4 		$16.3M Buy
2,340,845
+3,830
+0.2% +$26.4K 0.04% 614
2016
Q3 		$19.2M Buy
+2,337,015
New +$19.8M 0.05% 565

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Victory Capital Management's IOVA Position: Q1 2026 in Review

Victory Capital Management increased its Iovance Biotherapeutics (IOVA) stake by 3.8% in Q1 2026, buying an estimated $4.7K and bringing the position to 40,463 shares worth $142K. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

Victory Capital Management first reported a position in IOVA in Q3 2016 and has held it in 39 quarters since. The position peaked at $120M in Q1 2020. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Victory Capital Management held 40,463 shares of Iovance Biotherapeutics worth $142K as of Q1 2026.
  • Victory Capital Management bought 1,470 Iovance Biotherapeutics shares in Q1 2026, an estimated $4.7K.
  • Iovance Biotherapeutics made up ﹤0.01% of Victory Capital Management's portfolio in Q1 2026, its #2241 holding.
  • Victory Capital Management first reported a position in Iovance Biotherapeutics in Q3 2016 and has held it in 39 quarters since.
  • Victory Capital Management's Iovance Biotherapeutics position peaked at $120M in Q1 2020.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Victory Capital Management's 13F filing for Q1 2026, filed 15 May 2026.